PofoliaShared via Pofolia

iScience· 2026Q1

ATG16L2 as a prognostic biomarker and therapeutic target in kidney renal clear cell carcinoma

Xiaoqun Xu, Chaofeng Zhou, Rui Zhang, Congcong Fan et al.

Short summary

Elevated ATG16L2 expression in kidney renal clear cell carcinoma (KIRC) correlates with advanced disease and poorer survival, and its silencing attenuates tumor growth partly via Notch pathway modulation.

AI-generated from the title and abstract; the full text is not read.

Key points

  • ATG16L2 expression is elevated in KIRC tissues compared to normal tissues.
  • Higher ATG16L2 levels are associated with advanced KIRC stages and poorer overall survival.
  • Silencing ATG16L2 reduces KIRC cell proliferation, migration, and invasion.
  • ATG16L2 influences the tumor immune microenvironment and modulates the Notch signaling pathway.

AI-generated from the title and abstract; the full text is not read.

Abstract

Kidney renal clear cell carcinoma (KIRC) carries substantial clinical challenges. This study examined ATG16L2 , an autophagy-related gene family member, across TCGA, CPTAC, GEO, and an independent cohort to assess its expression patterns, clinicopathological associations, and prognostic relevance. Immune landscapes were characterized through CIBERSORT, ESTIMATE, xCell, and single-cell analyses. Functional investigations employed shRNA-mediated knockdown in KIRC cell lines and xenograft models, with attention to the Notch signaling pathway. ATG16L2 was elevated in KIRC and associated with advanced disease and poorer survival. Its expression correlated with altered immune infiltration and immune checkpoint levels. Silencing ATG16L2 attenuated proliferative, migratory, and invasive capacities, partly through Notch pathway modulation. These findings position ATG16L2 as a prognostic indicator and immune microenvironment modulator in KIRC, with implications for therapeutic strategies targeting the ATG16L2-Notch axis.

The authors' abstract, as published at the source. iScience, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Get it on Google Play Download on the App Store

Related papers

Field: Pulmonary and Respiratory Medicine

Pulmonary and Respiratory MedicineMedicine